Centers for Disease Control and Prevention, China   Report issue

Government Phase 1 Phase 2 Phase 3 Phase 4
Founded: Beijing China (1985)

Organization Overview

First Clinical Trial
2007
NCT00660257
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Centers for Disease Control and Prevention, China

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 1)

Adenoviridae Infections (Phase 1)

Critical Illness (Phase 2)

Encephalitis (Phase 4)

Encephalitis, Japanese (Phase 4)

Hemorrhagic Fever, Ebola (Phase 2)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

HIV Infections (Phase 1)

Immunologic Deficiency Syndromes (Phase 1)

Influenza, Human (Phase 3)

Kidney Diseases (Phase 4)

Measles (Phase 4)

Poliomyelitis (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Rubella (Phase 4)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 27
  • # of Trial APIs: 21